NanoViricides, Inc. (NYSE American: NNVC) has received approval from the Pillar Committee in Charge in the Democratic Republic of Congo to proceed with a proposed Phase II clinical trial evaluating its broad-spectrum antiviral NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak. The company believes this is the only orally administered Ebola treatment candidate currently under consideration for clinical testing.
NV-387 is designed to target host-cell features required by viruses, offering a broad-spectrum approach. The oral formulation could provide significant advantages in resource-limited outbreak settings, where intravenous treatments are often difficult to deploy and scale. The company noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment.
The next steps include obtaining approvals from the DRC National Ethics Committee and the regulatory agency ACOREP before initiating the study. NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles.
For more details, visit the full press release at https://nnw.fm/1ewVT. The latest news and updates relating to NNVC are available in the company’s newsroom at https://nnw.fm/NNVC.
